Single-molecule protein sequencing via photostable multicolor imaging
Photostable upconverting nanoparticles address the limitations of traditional protein sequencing by enabling precise, high-throughput single-molecule sequencing with improved spatial resolution and deep-tissue capabilities.
Patent Information
- Application Number
- PCT/US2026/026662
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-06
- Filing Date
- 2026-05-05
- Publication Date
- 2026-11-12
AI Technical Summary
Current protein sequencing technologies, particularly for single-cell and single-molecule applications, face challenges such as the need for orthogonal labeling strategies for amino acids, dynamic range issues, and limitations in detecting rare proteins, which are not addressed by existing methods like mass spectrometry and traditional Edman sequencing.
The development of photostable upconverting nanoparticles (UCNPs) conjugated to specific amino acid side chains, enabling precise sequencing through irradiation and measurement of emitted radiation patterns, allowing for orthogonal labeling and high-throughput single-molecule protein sequencing.
UCNPs provide photostability and narrow brightness distributions, enabling accurate sequencing of multiple amino acids simultaneously, reducing sequencing time and enhancing spatial resolution, suitable for deep-tissue imaging and high-density protein analysis.
Smart Images

Figure IMGF000002_0001 
Figure IMGF000007_0001 
Figure IMGF000008_0001
Abstract
Description
[0001] Attomey Docket No.: BRH-05725
[0002] Broad Ref. No.: BI-11332
[0003] SINGLE-MOLECULE PROTEIN SEQUENCING VIA PHOTOSTABLE MULTICOLOR IMAGING RELATED APPLICATIONS
[0004] This application claims the benefit of priority to U.S. Provisional Application No.
[0005] 63 / 800,668, filed May 6, 2025, the contents of which are incorporated herein by reference in their entirety.
[0006] BACKGROUND
[0007] Biological processes within organisms are carried out by complex interaction network of cells and molecules. Although virtually all cells in the body share an identical genome, the identity and functions of each cell are regulated at multiple layers, and thus characterizing the cellular heterogeneity is crucial to comprehensively understand these processes. With the advances in DNA sequencing, massive sets of single-cell genomic and transcriptomic data have revealed important biological insights. Proteomics awaits similar revolutionary technology development. Proteins are the players that carry out functions and the proteome cannot be directly predicted from the transcriptome. The development of spatially-resolved single-cell protein sequencing (scProtSeq) may fundamentally enhance our understanding of the heterogenous living systems, with a goal of correlating phenotypical measurements of healthy and disease samples with their proteomics. Single-cell protein sequencing is challenging in many fronts. First, nucleic acid detection can be easily achieved with its complementary strand while not all proteins have antibodies with high affinity. To target each amino acid, 20 orthogonal labeling strategies are required. Furthermore, the dynamic range of protein copy number is 4 orders of magnitude larger than that of mRNA. This presents an enormous challenge for mass spectrometry, which is the current gold standard for proteomics. The detection limit of mass spectrometry is 0.1 to 10 femtomole, and thus detecting rare proteins would require millions of cells. In view of the foregoing, there is an unmet need to improve protein sequencing technologies and methodologies, in particular for single-cell and singlemolecule applications.
[0008] SUMMARY OF THE INVENTION
[0009] In certain aspects, the present disclosure provides an upconverting nanoparticle, comprising:Attorney Docket No.: BRH-05725
[0010] Broad Ref. No.: BI-11332 i. a core comprising one or more activator ions and one or more emitter ions; wherein, upon excitation with radiation, the one or more activator ions emit radiation of a wavelength capable of exciting the one or more emitter ions;
[0011] ii. an optically inert shell enveloping the core; and
[0012] iii. a reactive shell comprising SiCh enveloping the optically inert shell; wherein the upconverting nanoparticle is conjugated to at least one group having a structure represented by formula (IV):
[0013] RB
[0014] rh
[0015] L
[0016] / RA
[0017] Rp
[0018]
[0019] (IV);
[0020] wherein:
[0021] represents the point of connection to the upconverting nanoparticle;
[0022] RA, L, and Rpare each independently a linker moiety or a bond; and
[0023] RBis a group capable of forming a covalent bond to an amino acid side chain or is absent.
[0024] In certain aspects, the present disclosure provides methods of sequencing a peptide, comprising:
[0025] i. labeling one or more amino acid residues of the peptide with at least one upconverting nanoparticle;
[0026] ii. irradiating the at least one upconverting nanoparticle;
[0027] iii. digesting the peptide;
[0028] iv. irradiating the at least one upconverting nanoparticle;
[0029] v. measuring the emitted radiation of the at least one upconverting nanoparticle; and vi. determining the sequence of the peptide by correlating a decrease in the measured emitted radiation with the sequence;
[0030] wherein the spectrum of the measured emitted radiation corresponds to a specific amino acid side chain.Attomey Docket No.: BRH-05725
[0031] Broad Ref. No.: BI-11332 BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 shows the phenotypic changes from functional readouts such as electrophysiology and single-particle tracking can be correlated and rationalized with scProtSeq.
[0032] FIG. 2A shows the sequential cleavage of the N-terminal amino acid during Edman sequencing. Each type of residue is labeled with different colors of UCNPs.
[0033] FIG. 2B shows images of scProtSeq where single proteins give rise to one point spread function and signals from different amino acids are split into different color channels.
[0034] FIG. 2C shows time traces from each amino acid. The protein sequence can be reconstructed from the pattern of signal loss.
[0035] FIG. 3A shows UCNP imaged in PBS and TFA, demonstrating the photostability of the UCNP emission signal to harsh acidic conditions.
[0036] FIG. 3B shows the brightness distribution of single dye and UCNP. Both samples contain small population of dimers. The separation of monomers and dimers is much more clear for UCNPs due to their narrower brightness distribution.
[0037] FIGs. 4A-4C show the process for thiolation / DNA conjugation of UCNPs of the present disclosure. FIG. 4A shows a schematic of DNA functionalization of UCNPs. To confirm conjugation, Cy5 dye functionalized cDNA is annealed, allowing for colocalization of UCNP signal with Cy5 signal. FIG. 4B shows an optical image of DNA-conjugated UCNPs excited by the 976 nm laser. FIG.4C shows the same field of view as in FIG.4B but excited by the 638 nm laser, showing the Cy5 signal.
[0038] FIG. 5 is a schematic showing the process for azidation / DNA conjugation of UCNPs of the present disclosure.
[0039] FIG. 6 is a schematic depicting the orthogonal amino acid-UCNP conjugation schemes for 9 amino acids. The points of attachment to the UCNP / linker moieties are represented by a sphere.
[0040] DETAILED DESCRIPTION OF THE INVENTION
[0041] Single-molecule imaging in tandem with upconverting nanoparticles (UCNPs) has the capability to perform spatially-resolved scProtSeq. Recent proof-of-principle work has shown potential of the single-molecule version of Edman sequencing. FIG. 1. Phenotypic changes from electrophysiology and single-particle tracking can be correlated and rationalized with scProtSeq. The present disclosure describes ultralong-term, single-molecule and single-cell characterization of protein-protein interactions. Traditional Edman sequencing consists ofAttomey Docket No.: BRH-05725
[0042] Broad Ref. No.: BI-11332 cyclic chemical reactions which label, cleave, and identify the N-terminal amino acid by chromatography (FIG. 2A). In the single-molecule fluorescence detection scheme, each type of amino acid is first labeled with a fluorophore of one color. Subsequently, the Edman reagent phenylisothiocyanate reacts with the N-terminal amino group and removes that amino acid. During each degradation cycle, the identity of the cleaved amino acid can be determined from the stepwise decrease of fluorescence signal (FIGs. 2B and 2C). With single-molecule detection sensitivity, this method can be highly parallel and can offer spatial information of proteins within a single cell. Despite great promise, there exists many technical challenges using dyes in this approach. First, most dyes were found to bleach by the harsh reaction and reagents used in Edman degradation.
[0043] In contrast, the photostable UCNP luminescence can survive in trifluoroacetic acid (TFA) with 84.9 ± 7.2% signal retention (FIG. 3A). Secondly, precise determination of the number of amino acids in each cycle is greatly hampered by the photo properties of dyes. Dyes are prone to photobleaching and so signal loss from dyes conjugated to the non-cleaved amino acids will lead to inaccurate sequence assignment. Moreover, the ability to accurately read out the number of fluorophores from stepwise signal loss is highly dependent on the brightness variation of single probes. FIG.3B shows that dyes have broad distributions of brightness with standard deviation over average (<T / Z) of 20%. In contrast, UCNPs are extremely photostable and exhibit very narrow brightness distributions (cr / / / = 5.5%), making them the ideal probes for quantal brightness analysis. FIG. 3B clearly demonstrates that the 12% dimer population in the mixture can be easily distinguished from the single UCNPs. Furthermore, the state-of-the-art single-molecule imaging is limited to imaging only 3-4 types of dyes simultaneously due to their significant spectral overlap. On the other hand, UCNPs have much sharper emission lines. In addition to colors, orthogonal conjugation schemes specific to the 20 amino acids are needed. In the first single-molecule Edman sequencing, the authors only demonstrated fingerprinting of one amino acid, Cysteine, using maleimide chemistry. The present disclosure provides at least eight orthogonal labeling schemes that can conjugate silica-coated UCNPs to Eys, Cys, Arg, Tyr, Trp, Met, His, and Asp / Glu residues. Even though not all 20 amino acids can be directly read out, computer simulations have revealed that even with partial sequencing of only 4 distinct amino acids, 98% of the human proteome can be uniquely mapped within 30 cycles. Thus, with the disclosed scheme of 8 labels based on multiplexed UCNPs, the sequencing time can be greatly reduced, enabling high throughput scProtSeq. Super-resolution imaging will be needed to spatially resolve individual protein molecules within single cells. To this end, the development of multicolor STED microscopy using UCNPs will increase theAttomey Docket No.: BRH-05725
[0044] Broad Ref. No.: BI-11332 spatial resolution by 20-30 fold to 10 nm, which will dramatically enhance the ability to resolve signals at high protein density. Additionally, by physically enlarging the sample up to 10-fold using expansion microscopy, the measurable protein density can be further increased. Photostable UCNPs remarkably outperform dyes in preserving fluorescence after expansion microscopy procedures. Ultimately, in situ sequencing needs to be performed in thick tissue blocks to fully uncover the complex interactions between cells in 3D environment. Imaging in thick tissue is limited by light scattering which greatly deteriorates imaging sensitivity. Similar to the quantum dots that emit in the short-wave infrared region, since rare-earth nanoparticles (RENPs) are excited by near-infrared light and can also emit infrared light, absorption and scattering are greatly reduced, making RENPs ideally suited for deep-tissue imaging. The present disclosure demonstrates background-free single particle imaging in both C. elegans and zebrafishes. Successful implementation of scProtSeq will provide a highly sensitive and parallelized proteomic technology, which is an important step towards understanding the complex relationship between the proteome and the phenotypes within heterogeneous 3D tissue environment. Single-cell protein sequencing is challenging in many fronts. The current gold standard for proteomics is mass spectrometry. Although the protein sequence can be accurately read out from mass spectra, the detection limit of mass spectrometry is 0.1 to 10 femtomole, and thus detecting rare proteins would require millions of cells. Single-molecule imaging may be used in tandem with UCNPs to perform spatially-resolved scProtSeq. Recent proof-of-principle work has shown potential of the single-molecule version of Edman sequencing. Despite great promise, there exists many technical challenges using dyes in this approach.
[0045] Furthermore, it is difficult to image more than 3-4 types of dyes simultaneously due to their significant spectral overlap. On the other hand, simultaneous multi-color imaging is possible using UCNPs. Thus, with the presently disclosed scheme of 8 labels based on multiplexed UCNPs, the sequencing time can be greatly reduced, enabling single molecule protein sequencing.
[0046] Peptide sequencing
[0047] The most widely used reaction for the sequential analysis of N-terminal residue of peptides is the Edman degradation method (Edman, et al. “Method for determination of the amino acid sequence in peptides”, Acta Chem. Scand. 4: 283-293 (1950), (herein incorporated by reference). Edman degradation is a method of sequencing amino acids in a peptide wherein the amino-terminal residue is labeled and cleaved from the peptide without disrupting the peptide bonds between other amino acid residues. In the Edman procedure phenylisothiocyanate reacts quantitatively with the free amino group of a peptide to yield theAttomey Docket No.: BRH-05725
[0048] Broad Ref. No.: BI-11332 corresponding phenylthiocarbamoyl peptide. On treatment with anhydrous acid the N-terminal residue is split off as a phenylthiocarbamoyl amino acid, leaving the rest of the peptide chain intact. The phenylthiocarbomyl amino acid is then cyclized to the corresponding phenylthiohydantin derivative, which can be separated and identified, usually by gas-liquid chromatography. Alternatively, the N-terminal residue removed as the phenylthiocarbamoyl derivative can be identified simply by determining the amino acid composition of the peptide before and after removal of the N-terminal residue; called the subtractive Edman method. The advantage of the Edman method is that the rest of the peptide chain after removal of the N-terminal amino acid is left intact for further cycles of this procedure; thus the Edman method can be used in a sequential fashion to identify several or even many consecutive amino acid residues starting from the N-terminal end. Edman and Begg have further exploited this advantage by utilizing an automated amino acid “sequenator” for carrying out sequential degradation of peptides by the phenylisothiocyanate procedure (Eur. J. Biochem. 1:80-91, (1967) [2], (herein incorporated by reference). In one embodiment, such automated amino acid sequencers permit up to 30 amino acids to be accurately sequenced with over 99% efficiency per amino acid (Niall et al. “Automated Edman degradation: the protein sequenator”. Meth. Enzymol. 27: 942-1010, (1973), (herein incorporated by reference). Nevertheless, the traditional Edman sequencing method does not have sensitivity down to the single molecule level.
[0049] In the single-molecule fluorescence detection scheme, each type of amino acid is first labeled with a fluorophore of one color. Subsequently, the Edman reagent phenylisothiocyanate reacts with the N-terminal amino group and removes that amino acid. During each degradation cycle, the identity of the cleaved amino acid can be determined from the stepwise decrease of fluorescence signal if that cleaved amino acid is labeled with a UCNP with a distinct color (FIGs 2B and 2C). For instance, in FIG. 2C, the amino acid cleaved during the first Edman degradation cycle is Met, and thus a stepwise decrease in UCNP signal in the color channel corresponding to Met will be observed. In the second Edman degradation cycle, Leu is cleaved. However, since there is no known conjugation chemistry for Leu so far, Leu is not labeled by a UCNP and hence no signal loss is detected in any color channels. Subsequently, three sequential Lys residues will be cleaved in cycles 3-5, which will result in three stepwise decreases in signal in the color channel corresponding to Lys. After several rounds of Edman degradation and fluorescence detection, we will obtain a readout sequence containing amino acids with known conjugation chemistry (Lys, Cys, Arg, Tyr, Trp, Met, His, and Asp / Glu) andAttorney Docket No.: BRH-05725
[0050] Broad Ref. No.: BI-11332 unknown amino acids (labeled as X). The true peptide identity can then be determined by mapping back to the human proteome.
[0051] Upconverting nanoparticles
[0052] In certain aspects, the present disclosure provides an upconverting nanoparticle, comprising:
[0053] i. a core comprising one or more activator ions and one or more emitter ions; wherein, upon excitation with radiation, the one or more activator ions emit radiation of a wavelength capable of exciting the one or more emitter ions;
[0054] ii. an optically inert shell enveloping the core; and
[0055] iii. a reactive shell comprising SiCh enveloping the optically inert shell;
[0056] wherein the upconverting nanoparticle is conjugated to at least one group having a structure represented by formula (IV):
[0057] RB
[0058] r
[0059] L
[0060] u
[0061] RA
[0062]
[0063] (IV);
[0064] wherein:
[0065] represents the point of connection to the upconverting nanoparticle;
[0066] RA, L, and Rpare each independently a linker moiety or a bond; and
[0067] RBis a group capable of forming a covalent bond to an amino acid side chain or is absent.
[0068] In certain embodiments, L is a linker moiety comprising a DNA oligonucleotide, or an RNA oligonucleotide. In some such embodiments, RAis a linker moiety conjugated to a 3' terminus of the oligonucleotide.
[0069] In certain embodiments, L is a linker moiety comprising an RNA oligonucleotide. In other embodiments, L is a linker moiety comprising a DNA oligonucleotide. In some such embodiments, the DNA oligonucleotide comprises the sequence: TATACATCTAT (SEQ. ID No. 1) In some such embodiments, the DNA oligonucleotide has the following sequence: 5'-TATACATCTAT-3' (SEQ. ID No. 2).Attorney Docket No.: BRH-05725
[0070] Broad Ref. No.: BI-11332 In certain embodiments, L comprises about 1-30 nucleotides. In certain preferred embodiments, L comprises about 1-10 nucleotides, about 1-20 nucleotides, or about 1-30 nucleotides. In certain preferred embodiments, L comprises about 10-20 nucleotides.
[0071] In certain embodiments, Rpis a linker moiety comprising (poly)ethylene glycol. In certain such embodiments, Rpis a linker moiety comprising (poly)ethylene glycol comprising about 1-1,000 repeat units, about 1-2,000 repeat units, about 1-3,000 repeat units, about 1- 4,000 repeat units, about 1-5,000 repeat units, about 1-6,000 repeat units, about 1-7,000 repeat units, about 1-8,000 repeat units, about 1-9,000 repeat units, or about 1-10,000 repeat units.
[0072] In certain embodiments, RAcomprises a group selected from
[0073]
[0074] wherein:
[0075] R1, R2, R3, R4, R5, and R6are each independently a linker moiety or a bond.
[0076] In certain embodiments, RAis selected from
[0077]
[0078]
[0079] represents the point of connection to Rp, and represents the point of connection to L. In some embodiments, L is a DNA oligonucleotide.
[0080] In certain embodiments, RBis present. In some preferred embodiments, RBis a group capable of forming a covalent bond to an amino acid side chain. In certain such embodiments, the group capable of forming a covalent bond to an amino acid side chain is a residue-specific peptide labeling group. In some preferred embodiments, the residue-specific peptide labelingAttorney Docket No.: BRH-05725
[0081] Broad Ref. No.: BI-11332 group is a group capable of forming a covalent bond to a lysine, cysteine, arginine, tyrosine, tryptophan, methionine, histidine, aspartate, or a glutamate residue.
[0082]
[0083] wherein:
[0084] represents the point of connection to L. In some embodiments, L is a DNA oligonucleotide. In some such embodiments, RBis conjugated to a 5' terminus of the DNA oligonucleotide.
[0085] In certain embodiments, the upconverting nanoparticle has a diameter of about 3-20 nm. In further preferred embodiments, the upconverting nanoparticle has a diameter of about 10 nm. In certain embodiments, the one or more activator ions are lanthanide ions. In further embodiments, the one or more activator ions are selected from Lu3+, Yb3+, Ho3+, Pr3+, Nd3+, EU3+, Tb3+, Dy3+, Ce3+, Sm3+, and La3+, or a combination thereof. In yet further embodiments, the one or more activator ions are Yb3+. In certain embodiments, the one or more emitter ions are lanthanide ions. In further embodiments, the one or more emitter ions are selected from LU3+, Er3+, Tm3+, Ho3+, Pr3+, Nd3+, Eu3+, Tb3+, Dy3+, Ce3+, Sm3+, and La3+, or a combination thereof. In yet further embodiments, the one or more emitter ions are Er3+, Tm3+, or a combination thereof.
[0086] In certain embodiments, the core has an average diameter of about 3-10 nm. In further, preferred embodiments, the core has an average diameter of about 3 nm. In certain embodiments, the optically inert shell has an average thickness of about 0.5-8 nm. In furtherAttomey Docket No.: BRH-05725
[0087] Broad Ref. No.: BI-11332 embodiments, the optically inert shell has an average thickness of about 1 nm. In certain especially preferred embodiments, the optically inert shell comprises P-NaYo.8Gdo.2F4.
[0088] In further embodiments, the core comprises -NaYbi-xLnxF4, wherein Ln is selected from Yb3+, Er3+, and Tm3+, and wherein x is from 0 to 1. In yet further embodiments, the core comprises NaY(i-x-y)Yb(y)Tm(X)F4, and wherein (x+y) = 1. In still further embodiments, the core comprises NaY(i-x-y)Yb(y)Er(X)F4, and wherein (x+y) = 1. In certain embodiments, x is from 0 to 1. In further embodiments, y is from 0 to 1. In yet further embodiments, x is from 0 to 0.5, and y is from 0.5 to 1. In still further embodiments, x is from 0 to 0.25, and y is from 0.75 to 1. In certain embodiments, the core comprises NaYbo.9Ero.1F4. In further embodiments, the core comprises NaYbo.85Tmo.15F4. In yet further embodiments, the core comprises NaY0.69Yb0.30Tm0.01F4.
[0089] In certain preferred embodiments, the core does not comprise a seed crystal that does not contain activator ions or emitter ions.
[0090] In certain embodiments, the upconverting nanoparticle has an emission spectrum when excited with infrared radiation having a wavelength ranging from about 860 nm to about 1500 nm. In further embodiments, the infrared radiation has a wavelength ranging from about 900 nm to about 1400 nm. In yet further embodiments, the infrared radiation has a wavelength of about 976 nm. In still further embodiments, the emission spectrum comprises about 1-10 peaks, wherein each peak has a wavelength ranging from about 350 nm to about 850 nm. In certain embodiments, the emission spectrum comprises about 1-10 peaks, wherein each peak has a wavelength ranging from about 850 nm to about 1500 nm.
[0091] In certain embodiments, the upconverting nanoparticle continues to emit a spectrum of radiation at a substantially constant intensity after about 15 hours of exposure to radiation at a wavelength of 976 nm and a power density of about 5-30 kW / cm2. In certain embodiments, the upconverting nanoparticle emits substantially continuous radiation during exposure to radiation at a wavelength of 976 nm and a power density of about 5-30 kW / cm2.
[0092] In certain embodiments, the upconverting nanoparticle further comprises a reactive shell comprising SiQ? enveloping the optically inert shell. In further embodiments, the reactive shell has a thickness of about 0.5-6 nm. In yet further, preferred embodiments, the reactive shell has a thickness of about 0.5 nm. In certain embodiments, the reactive shell is functionalized with an organic compound (e.g., a fluorophore, a peptide, a nucleic acid, an affinity tag, such as biotin, an enzyme, or a drug).
[0093] In certain especially preferred embodiments, the present disclosure provides compositions comprising a plurality of upconverting nanoparticles disclosed herein, whereinAttomey Docket No.: BRH-05725
[0094] Broad Ref. No.: BI-11332 the plurality of upconverting nanoparticles is substantially uniform in size, composition, shape, and / or molecular weight. In further preferred embodiments, the plurality of upconverting nanoparticles is substantially monodisperse. In yet further embodiments, the polydispersity index of the plurality of upconverting nanoparticles is between about 1% and about 10%. In still further embodiments, the polydispersity index of the plurality of upconverting nanoparticles is between about 3% and about 7%. In certain preferred embodiments, the poly dispersity index of the plurality of upconverting nanoparticles is between 3.8% and 6.2%.
[0095] Methods of Sequencing
[0096] In certain aspects, the present disclosure provides methods of sequencing a peptide, comprising:
[0097] i. labeling one or more amino acid residues of the peptide with at least one upconverting nanoparticle;
[0098] ii. irradiating the at least one upconverting nanoparticle;
[0099] iii. digesting the peptide;
[0100] iv. irradiating the at least one upconverting nanoparticle;
[0101] v. measuring the emitted radiation of the at least one upconverting nanoparticle; and vi. determining the sequence of the peptide by correlating a decrease in the measured emitted radiation with the sequence;
[0102] wherein the spectrum of the measured emitted radiation corresponds to a specific amino acid side chain.
[0103] In certain embodiments, the at least one upconverting nanoparticle is an upconverting nanoparticle according to the present disclosure.
[0104] In certain embodiments, the methods further comprise resolving a spatial location of the peptide within a single cell.
[0105] In certain embodiments, the decrease in the measured emitted radiation is a stepwise decrease in the measured emitted radiation.
[0106] In certain embodiments, the one or more amino acid residues of the peptide are selected from lysine, cysteine, arginine, tyrosine, tryptophan, methionine, histidine, aspartate, and glutamate.
[0107] In certain embodiments, labeling one or more amino acid residues of the peptide with at least one upconverting nanoparticle comprises conjugating a first amino acid side chain to an upconverting nanoparticle having a first emission spectrum, and conjugating a second amino acid side chain to an upconverting nanoparticle having a second emission spectrum, wherein the first emission spectrum and the second emission spectrum are substantially different.Attomey Docket No.: BRH-05725
[0108] Broad Ref. No.: BI-11332 In certain embodiments, the methods comprise conjugating a third, fourth, fifth, sixth, seventh, eighth, and / or ninth amino acid side chain to an upconverting nanoparticle having a third, fourth, fifth, sixth, seventh, eighth, and / or ninth emission spectrum; wherein each emission spectrum is substantially different.
[0109] In certain embodiments, the amino acid side chain is selected from a lysine amino acid side chain, a cysteine amino acid side chain, an arginine amino acid side chain, a tyrosine amino acid side chain, a tryptophan amino acid side chain, a methionine amino acid side chain, a histidine amino acid side chain, an aspartate amino acid side chain, and a glutamate amino acid side chain.
[0110] In certain embodiments, at least one amino acid side chain is a lysine amino acid side chain. In further embodiments, at least one amino acid side chain is a cysteine amino acid side chain. In yet further embodiments, at least one amino acid side chain is an arginine amino acid side chain. In still further embodiments, at least one amino acid side chain is a tyrosine amino acid side chain. In certain embodiments, at least one amino acid side chain is a tryptophan amino acid side chain. In further embodiments, at least one amino acid side chain is a methionine amino acid side chain. In yet further embodiments, at least one amino acid side chain is a histidine amino acid side chain. In still further embodiments, at least one amino acid side chain is an aspartate amino acid side chain. In certain embodiments, at least one amino acid side chain is a glutamate amino acid side chain.
[0111] In certain embodiments, digesting the peptide comprises:
[0112] i. contacting the peptide with a degradation reagent; and
[0113] ii. contacting the peptide with an acid.
[0114] In some embodiments, the degradation reagent is phenylisothiocyanate (PITC). In certain embodiments, the acid is trifluoroacetic acid.
[0115] In certain embodiments, the methods further comprise repeating steps iii.-vi. for between about 1-50 cycles. In certain such embodiments, the methods further comprise repeating steps iii.-vi. for between about 1-10 cycles, about 1-20 cycles, about 1-30 cycles, about 1-40 cycles, or about 1-50 cycles. In certain such embodiments, the methods further comprise repeating steps iii.-vi. for at least about 1 cycle, about 5 cycles, about 10 cycles, about 15 cycles, about 20 cycles, about 25 cycles, about 30 cycles, about 35 cycles, about 40 cycles, or about 45 cycles. In some preferred embodiments, the method further comprises repeating steps iii.-vi. for about 30 cycles.Attomey Docket No.: BRH-05725
[0116] Broad Ref. No.: BI-11332 In certain embodiments, digesting the peptide comprises performing at least one Edman degradation cycle. In certain such embodiments, each Edman degradation cycle removes one amino acid residue from the N-terminus of the peptide.
[0117] In certain embodiments, correlating the measured emitted radiation with the sequence of the peptide comprises integrating an intensity of the measured emitted radiation following steps ii.-v. In certain embodiments, the intensity of the measured emitted radiation is integrated at each cycle.
[0118] In certain embodiments, correlating the measured emitted radiation with the sequence of the peptide comprises measuring at least one change in an intensity of the measured emitted radiation following steps ii.-v. In some embodiments, measuring the at least one change in the intensity of the measured emitted radiation provides an identity of an amino acid residue that is removed at each cycle. In some such embodiments, the at least one change in the intensity of the measured emitted radiation is a decrease in the intensity of the measured emitted radiation. In some such embodiments, the decrease is a stepwise decrease.
[0119] Optical microscopy has been a foundational method to study cellular processes. Notably, single-molecule microscopy has revolutionized the way we investigate biomolecular structure and dynamics by enabling the direct visualization of molecular interactions in realtime and reveals variations in molecular behavior that are hidden in ensemble measurements. Single-particle tracking (SPT) has illuminated a wide range of phenomena on a single molecule basis, including the dynamics of organelle interactions, mitochondrial crista, apoptosis, membrane receptors, motor proteins, and synaptic clefts. This technology allows monitoring of the motions of individual molecules with spatial resolution down to tens of nanometers, depending on the brightness of the probe.
[0120] Single-particle tracking can be achieved with a wide range of probes, including organic dyes, fluorescent proteins, quantum dots, and metal nanoparticles. However, many probes still face limitations, particularly in photostability, toxicity, and the number of colors one can simultaneously image. Organic dyes and fluorescent proteins photobleach within tens of seconds, while quantum dots suffer from intermittent dark states and can be cytotoxic, depending on their functionalization. Photo-instability of these probes hinders the ability to continuously image the dynamics of single molecules for an extended period, which is essential for uncovering many biological processes. Gold or silver nanoparticles are photostable, but their size is relatively large (>30 nm).
[0121] Numerous strategies have been developed to reduce fluorophore photobleaching and blinking, such as employing enzymatic oxygen-scavenging systems or addition of triplet-stateAttomey Docket No.: BRH-05725
[0122] Broad Ref. No.: BI-11332 quenchers either in solution or directly conjugated to the fluorophores. Recently, blinking of quantum dots has been greatly suppressed. However, toxicity remains a concern for using these probes in live cells. Longer SPT was obtained by using biomolecular scaffolds that assemble multiple fluorescent proteins or dyes, but these methods are still limited to the timescale of few minutes.
[0123] Current multiplex methods require excitation sources of different wavelengths or sequential imaging. Moreover, the broad and featureless emission spectra of reported SPT probes limit the number of colors concurrently imaged. Expanding the array of simultaneous colors enables the study of interactions and colocalizations on a single-molecule level. This could significantly increase the number of targets in highly multiplexed imaging techniques such as MERFISH, seqFISH, and STARmap.
[0124] To overcome these limitations, rare-earth doped Upconverting Nanoparticles (UCNPs) may be utilized, which have been shown to be extremely photostable, bright and non-toxic, which makes them promising bio-imaging probes. UCNPs do not blink or bleach, even after hours of excitation.
[0125] UCNPs are doped with activator ions such as Yb3+, a lanthanide which absorbs nearinfrared excitation at 976 nm. The absorbed energy can be transferred to the co-doped emitter ions such as Er3+and Tm3+via multiphoton (upconversion) processes. Upconversion between near-infrared excitations to visible emission provides nearly background-free imaging by eliminating autofluorescence that is often seen when using visible laser excitations. Furthermore, UCNPs have much sharper emission lines. Spectrally pure UCNPs can be generated by doping UCNPs with different rare-earth ions enabling multiplexed imaging using a single excitation source. Despite UCNPs’ high photostability and anti-stokes shifts, their relatively large size (>20 nm) could perturb the dynamics of the labeled molecules and limit the current applications to studying larger complexes, such as cargo transport. Existing reports of smaller UCNPs show the field has not yet achieved brightness suitable for SPT with high temporal resolution and limited excitation-induced cell damage. Thus, smaller probes may retain effective brightness for SPT at high frame rates and low power densities. Furthermore, these probes are promising tools for illustrative applications such as nucleotide sequencing, or as color sources in display screens (e.g., television screens).
[0126] More highly multiplexed palettes of UCNPs can be accessed by fine-tuning the emission spectrum of these small UCNPs. These photostable and multiplexed probes open new avenues for numerous and diverse biological applications by enabling imaging of molecular interactions in real time at the single molecule level, and for a prolonged period.Attomey Docket No.: BRH-05725
[0127] Broad Ref. No.: BI-11332 Accordingly, the present disclosure describes upconverting nanoparticles with tunable emissive properties, which may be further functionalized and are suitable for a range of applications, including, but not limited to, single-particle tracking, live-cell imaging, nucleotide sequencing, or use in color displays. The present disclosure further describes methods by which to produce said upconverting nanoparticles.
[0128] The upconverting nanoparticles of this disclosure generally comprise lanthanide ions of the form MLnX4, where Ln is a lanthanide ion, X is a halide ion, and M is an alkali metal ion. In preferred embodiments, Na+or K+ions can be used as the alkali metal ion. The crystal lattice of the UCNPs imparts several important properties upon the UCNPs for facilitating energy transfer. In preferred embodiments, the crystal lattice has a low lattice phonon energy, is highly chemically stable, and has low symmetry. Each of these features raises the efficiency of photon upconversion. In preferred embodiments, the UCNPs of this disclosure comprise ions with similar ionic radii, which improve these properties of the crystal lattice, and in turn improve upconversion. The selection of activator and emitter ions is typically also dependent on the ions’ photophysical properties. Appropriate selections of activator and emitter ion will minimize non-radiative energy loss and maximize photon absorption and energy transfer. The selection of halide is also important; in preferred embodiments, the UCNPs of this disclosure comprise fluoride, as it is chemically stable and has a low phonon energy. In especially preferred embodiments, the UCNPs of this disclosure are core-shell structured, comprising an internal, approximately spherical core, and an external, approximately spherical shell enveloping the core. In preferred embodiments, the cores range in size from about 5 nm in diameter to about 20 nm in diameter, while the external shells may range in thickness from about 0.5 nm to about 8 nm. In certain embodiments, the UCNPs comprise an infrared-inert lanthanide ion such as gadolinium or yttrium, as well as dopant activator and emitter ions as described above. The doping ratio of both activator and emitter ions may vary, such that the preferred empirical formula of a UCNP may range from, for example, NaY(o.2o-o.so)Yb(o.o5- o.4O)Tm(o.oi-o.i5)F4. The optical characteristics of the UCNPs are a function of multiple factors, such as the size of the core, the thickness of the external shell, and of the doping ratios of activator and emitter ions. The particles disclosed herein can be tuned to emit radiation with a wavelength ranging from the visible into the infrared, or from about 400 nm to about 1000 nm when activated with infrared radiation. The photophysical features of the emission spectra are also dependent on the physical characteristics of the UCNPs; for example, a polydisperse sample of particles will have a broader emission spectrum than a monodisperse sample that is otherwise identical in composition, because particles with different physical characteristics willAttomey Docket No.: BRH-05725
[0129] Broad Ref. No.: BI-11332 differ in their individual emission characteristics. Similarly, aggregation of the UCNPs can result in broader emission. As a result, the parameters of the synthetic route used to access the UCNPs, which influences the physical characteristics of the particles, also has a strong influence on the optical properties. Accordingly, preferred compositions of UCNPs according to the disclosure will be highly uniform or monodisperse to ensure that the collection of UCNPs, and each UCNP within it, will emit radiation within a narrow band of wavelengths. Methods for achieving substantial monodispersity and low aggregation are disclosed herein.
[0130] UCNPs can also be coated in a layer of silicon dioxide, which enables the UCNPs to be functionalized with organic compounds. In addition to their photophysical properties, this can impart secondary functionality to the UCNPs, illustrative examples including modifying the solubility of the particles, enabling the particles to target biomolecules, enabling the particles to bind or interact with specific targets, or enabling the particles to label or deliver an organic payload.
[0131] UCNPs can be characterized and assessed for uniformity by a range of experimental techniques, which may include, but are not limited to, optical microscopy, electron microscopy, zeta potential, dynamic light scattering, dynamic image analysis, static image analysis, laser diffraction, inductively-coupled plasma-mass spectrometry (ICP-MS), or X-ray fluorescence.
[0132] Definitions
[0133] Unless otherwise defined herein, scientific and technical terms used in this application shall have the meanings that are commonly understood by those of ordinary skill in the art. Generally, nomenclature used in connection with, and techniques of, chemistry, cell and tissue culture, molecular biology, cell and cancer biology, neurobiology, neurochemistry, virology, immunology, microbiology, pharmacology, genetics and protein and nucleic acid chemistry, described herein, are those well known and commonly used in the art.
[0134] The methods and techniques of the present disclosure are generally performed, unless otherwise indicated, according to conventional methods well known in the art and as described in various general and more specific references that are cited and discussed throughout this specification. See, e.g. “Principles of Neural Science”, McGraw-Hill Medical, New York, N.Y. (2000); Motulsky, “Intuitive Biostatistics”, Oxford University Press, Inc. (1995); Uodish et al., “Molecular Cell Biology, 4th ed.”, W. H. Freeman & Co., New York (2000); Griffiths et al., “Introduction to Genetic Analysis, 7th ed.”, W. H. Freeman & Co., N.Y. (1999); and Gilbert et al., “Developmental Biology, 6th ed.”, Sinauer Associates, Inc., Sunderland, MA (2000).Attomey Docket No.: BRH-05725
[0135] Broad Ref. No.: BI-11332 Chemistry terms used herein, unless otherwise defined herein, are used according to conventional usage in the art, as exemplified by “The McGraw-Hill Dictionary of Chemical Terms”, Parker S., Ed., McGraw-Hill, San Francisco, C.A. (1985).
[0136] All of the above, and any other publications, patents and published patent applications referred to in this application are specifically incorporated by reference herein. In case of conflict, the present specification, including its specific definitions, will control.
[0137] As used herein, the term “optically inert” refers to the property of lacking substantial interaction with electromagnetic radiation within a desired range of the electromagnetic spectrum. For example, a fluorescent probe with an emission spectrum in the ultraviolet range could be considered optically inert in the infrared range. In certain embodiments, the present disclosure provides materials that are optically inert in the infrared range.
[0138] As used herein, the terms “upconverting” and “upconversion” refer to a photophysical process of anti-Stokes emission in which at least two lower-energy photons are absorbed by an object, thereby exciting the object, whereupon a single, higher-energy photon is emitted upon relaxation to the ground state.
[0139] As used herein, the terms “average diameter” and “average thickness” refer to values obtained though transmission electron microscopy by imaging and measuring the area of a minimum of 700 nanoparticles and calculating the diameter (d = 2v / ~(A / jt)). The mean value (“average diameter”) and standard deviation can then be calculated and used to determine the shell thickness.
[0140] As used herein, the term “poly dispersity index” refers to a quantification of the heterogeneity in average diameter of a plurality of upconverting nanoparticles, as calculated by the standard deviation divided by the average diameter. The standard deviation and average diameter can be obtained through any of the methods described above.
[0141] As used herein, the term “residue-specific peptide labeling group” refers to a functional group capable of forming a covalent bond to a specific amino acid residue, such as Cys, Eys, Tyr, Trp, Arg, Met, His, Asp, or Glu, which may or may not be part of a peptide or polypeptide. Exemplary residue-specific labeling groups are described in, e.g., Dovgan, I. et al. Organic & Biomolecular Chemistry 2018, 16, (8), 1305-1311; Seki, Y. etal. J. Am. Chem. Soc. 2016, 138, (34), 10798-801; Taylor, M. T. et al. Nature 2018, 562, (7728), 563-568; and Chen, G. et al. J. Am. Chem. Soc. 2003, 125, (27), 8130-3; which are incorporated herein by reference in their entireties.Attorney Docket No.: BRH-05725
[0142] Broad Ref. No.: BI-11332 EXAMPLES
[0143] The invention now being generally described, it will be more readily understood by reference to the following examples which are included merely for purposes of illustration of certain aspects and embodiments of the present invention and are not intended to limit the invention.
[0144] Exemplary UCNPs are described in U.S. Provisional Patent Application Number 63 / 553,882, filed February 15, 2025; and PCT / US25 / 15490, filed February 12, 2025, the contents of each of which are incorporated herein by reference in their entireties.
[0145] Example 1: Exemplary Single-Cell Protein Sequencing Protocol
[0146] Sample Preparation
[0147] Cells are first rinsed with phosphate-buffered saline (PBS), then are fixed using 3% formaldehyde and 0.1% glutaraldehyde in PBS at room temperature for 10 minutes. After fixation, cells are permeabilized in blocking buffer (3% bovine serum albumin [BSA], 0.5% Triton X-100 in PBS) for 10 minutes. To label amino acids with upconversion nanoparticles (UCNPs) of different colors, cells are incubated in 1% casein (Sigma) in medium for 5 minutes to block nonspecific binding. Subsequently, 1 nM of UCNPs — each conjugated to a distinct amino acid-targeting group and diluted in lx PBS — is added, and cells are incubated for 15 minutes. Additional labeling steps may be required for certain amino acids, as described in the literature. Unbound UCNPs are removed by washing with 1% casein-containing medium. Total-Internal-Reflection Fluorescence (TIRF Microscopy
[0148] Widefield imaging is performed using a custom-built microscope equipped with two excitation sources: a Thorlabs 976 nm fiber-coupled laser (P.N. BL976-PAG900) and a Cobolt 638 nm free-space laser (P.N. 06-MLD). The 976 nm laser is directed through a 950 nm dichroic mirror into a Nikon 60x oil-immersion objective (NA 1.49), with the sample mounted above. A motorized mirror allows displacement of the excitation beam to the periphery of the objective’s back focal plane, enabling switching between epifluorescence and TIRF illumination. The TIRF penetration depth is approximately 150 nm, effectively reducing background from out-of-focus fluorescence. Samples are irradiated at power densities ranging from 1 to 30 kW / cm2. Emission is collected by the same objective and is passed through the 950 nm dichroic into the detection path. The emission is focused by a 400 mm tube lens and is filtered with a 950 nm short-pass filter. After passing through an iris, the emission enters a dark box and is sequentially split into four spectral channels using three dichroic mirrors (cutoffs at 510 nm, 610 nm, and 705 nm). Each channel is directed by a dedicated mirror through a 255Attomey Docket No.: BRH-05725
[0149] Broad Ref. No.: BI-11332 mm collimating lens, then is recombined using a symmetric arrangement of dichroics. Prior to detection, the signal is focused by a 300 mm lens, resulting in an image scale of 100 nm per pixel. The four emission channels are directed to separate quadrants of the camera sensor, and the iris is adjusted to prevent crosstalk. Single-molecule imaging is conducted with a 0.1 s exposure time prior to each Edman degradation cycle.
[0150] Edman degradation
[0151] For single-molecule Edman sequencing, the perfusion chamber and the microscope objective are heated to 40 °C. Edman reagents are degassed by bubbling dry nitrogen gas for 10 minutes and are kept under nitrogen throughout the experiment. Solvent exchanges are automated via custom Python scripts and synchronized with image acquisition through MicroManager. The reagent delivery protocol is as follows:
[0152] • Wash with PBS for 1 min
[0153] • Wash with methanol for 1 min
[0154] • Wash with:
[0155] 1. Acetonitrile:pyridine:triethylamine:water (10:3:2:1, v / v)
[0156] 2. Acetonitrile:triethylamine (2:1, v / v) for 5 min
[0157] • Incubate with either 100% acetonitrile or acetonitrile:phenylisothiocyanate (9:1, v / v) for 30 min
[0158] • Wash with:
[0159] 1. Acetonitrile:pyridine:triethylamine:water (10:3:2:1, v / v)
[0160] 2. Acetonitrile:triethylamine (2:1, v / v) for 1 min
[0161] • Wash with ethyl acetate (Solution A) or acetonitrile (Solution B) for 1 min
[0162] • Cleave with 100% trifluoroacetic acid for 30 min
[0163] • Wash with ethyl acetate for 1 min
[0164] • Wash with water for 1 min
[0165] • Wash with methanol for 1 min
[0166] Data analysis: single-molecule localization
[0167] Localization of point-spread functions (PSFs) and trajectory reconstruction are performed using the MATLAB-based software slimfast2. Multichannel image registration is carried out using large UCNPs that emit in all four channels. Coarse alignment is achieved with individual steering mirrors for each channel, while fine registration is performed by identifying PSFs visible in all four channels and generating transformation matrices. These transformation matrices are applied across all frames, yielding registration errors in the range of 5-20 nm.Attomey Docket No.: BRH-05725
[0168] Broad Ref. No.: BI-11332 Custom MATLAB scripts are used to decode PSF colors and infer peptide sequences at each molecular position.
[0169] INCORPORATION BY REFERENCE
[0170] All publications and patents mentioned herein are hereby incorporated by reference in their entirety as if each individual publication or patent was specifically and individually indicated to be incorporated by reference. In case of conflict, the present application, including any definitions herein, will control.
[0171] EQUIVALENTS
[0172] While specific embodiments of the subject invention have been discussed, the above specification is illustrative and not restrictive. Many variations of the invention will become apparent to those skilled in the art upon review of this specification and the claims below. The full scope of the invention should be determined by reference to the claims, along with their full scope of equivalents, and the specification, along with such variations.
Claims
Attomey Docket No.: BRH-05725Broad Ref. No.: BI-11332 We claim:
1. An reconverting nanoparticle comprising:i. a core comprising one or more activator ions and one or more emitter ions; wherein, upon excitation with radiation, the one or more activator ions emit radiation of a wavelength capable of exciting the one or more emitter ions;ii. an optically inert shell enveloping the core; andiii. a reactive shell comprising SiCh enveloping the optically inert shell; wherein the upconverting nanoparticle is conjugated to at least one group having a structure represented by formula (IV):RBrLuzRARP(IV);wherein:represents the point of connection to the upconverting nanoparticle;RA, L, and Rpare each independently a linker moiety or a bond; andRBis a group capable of forming a covalent bond to an amino acid side chain or is absent.
2. The upconverting nanoparticle of claim 1, wherein L is a linker moiety comprising a DNA oligonucleotide or an RNA oligonucleotide.
3. The upconverting nanoparticle of claim 2, wherein L is a linker moiety comprising an RNA oligonucleotide.
4. The upconverting nanoparticle of claim 2, wherein L is a linker moiety comprising a DNA oligonucleotide.
5. The upconverting nanoparticle of any one of claims 2-4, wherein RAis a linker moiety conjugated to a 3' terminus of the oligonucleotide.Attorney Docket No.: BRH-05725Broad Ref. No.: BI-11332 6. The upconverting nanoparticle of any one of claims 2-5, wherein L comprises about 1-30 nucleotides.
7. The upconverting nanoparticle of claim 6, wherein L comprises about 1-10 nucleotides, about 1-20 nucleotides, or about 1-30 nucleotides.
8. The upconverting nanoparticle of claim 6 or 7, wherein L comprises about 10-20 nucleotides.
9. The upconverting nanoparticle of any one of claims 4-8, wherein the DNA oligonucleotide comprises the sequence: TATACATCTAT (SEQ. ID No. 1).
10. The upconverting nanoparticle of claim 9, wherein the DNA oligonucleotide has the following sequence: 5'-TATACATCTAT-3' (SEQ. ID No. 2).
11. The upconverting nanoparticle of any one of claims 1-10, wherein Rpis a linker moiety comprising (poly)ethylene glycol.
12. The upconverting nanoparticle of claim 11, wherein Rpis a linker moiety comprising (poly)ethylene glycol comprising about 1-1,000 repeat units, about 1-2,000 repeat units, about 1-3,000 repeat units, about 1-4,000 repeat units, about 1-5,000 repeat units, about 1-6,000 repeat units, about 1-7,000 repeat units, about 1-8,000 repeat units, about 1-9,000 repeat units, or about 1-10,000 repeat units.
13. The upconverting nanoparticle of any one of claims 1-12, wherein RAcomprises a o ,R2owherein:R1, R2, R3, R4, R5, and R6are each independently a linker moiety or a bond.Attorney Docket No.: BRH-05725Broad Ref. No.: BI-11332 14. The upcon verting nanoparticle of claim 13, wherein RAis selected fromrepresents the point of connection to Rp, andrepresents the point of connection to L.
15. The upconverting nanoparticle of claim 14, wherein L is a DNA oligonucleotide.
16. The upconverting nanoparticle of any one of claims 1-15, wherein RBis present.
17. The upconverting nanoparticle of claim 16, wherein RBis a group capable of forming a covalent bond to an amino acid side chain.
18. The upconverting nanoparticle of claim 17, wherein the group capable of forming a covalent bond to an amino acid side chain is a residue-specific peptide labeling group.
19. The upconverting nanoparticle of claim 18, wherein the residue-specific peptide labeling group is a group capable of forming a covalent bond to a lysine, cysteine, arginine, tyrosine, tryptophan, methionine, histidine, aspartate, or a glutamate residue.Attorney Docket No.: BRH-05725Broad Ref. No.: BI-11332 20. The upcon verting nanoparticle of any one of claims 16-19, wherein RBis selectedwherein:represents the point of connection to L.
21. The upconverting nanoparticle of claim 20, wherein L is a DNA oligonucleotide.
22. The upconverting nanoparticle of claim 21, wherein RBis conjugated to a 5' terminus of the DNA oligonucleotide.
23. The upconverting nanoparticle of any one of claims 1-22, wherein the one or more activator ions are lanthanide ions.
24. The upconverting nanoparticle of any one of claims 1-23, wherein the one or more activator ions are selected from Lu3+, Yb3+, Ho3+, Pr3+, Nd3+, Eu3+, Tb3+, Dy3+, Ce3+, Sm3+, and La3+, or a combination thereof.
25. The upconverting nanoparticle of any one of claims 1-24, wherein the one or more activator ions are Yb3+.
26. The upconverting nanoparticle of any one of claims 1 -25, wherein the one or more emitter ions are lanthanide ions.Attomey Docket No.: BRH-05725Broad Ref. No.: BI-11332 27. The upconverting nanoparticle of claim 26, wherein the one or more emitter ions are selected from Lu3+, Er3+, Tm3+, Ho3+, Pr3+, Nd3+, Eu3+, Tb3+, Dy3+, Ce3+, Sm3+, and La3+, or a combination thereof.
28. The upconverting nanoparticle of claim 26 or 27, wherein the one or more emitter ions are Er3 -, Tm3+, or a combination thereof.
29. The upconverting nanoparticle of any one of claims 1-28, wherein the optically inert shell comprises P-NaYo.sGdo.2F4.
30. The upconverting nanoparticle of any one of claims 1-29, wherein the core does not comprise a seed crystal that does not contain activator ions or emitter ions.
31. The upconverting nanoparticle of any one of claims 1-30, wherein the at least one upconverting nanoparticle has an emission spectrum when excited with infrared radiation having a wavelength ranging from about 860 nm to about 1500 nm.
32. The upconverting nanoparticle of claim 31, wherein the infrared radiation has a wavelength ranging from about 900 nm to about 1400 nm.
33. The upconverting nanoparticle of claim 32, wherein the infrared radiation has a wavelength of about 976 nm.
34. The upconverting nanoparticle of any one of claims 31-33, wherein the emission spectrum comprises about 1-10 peaks, and wherein each peak has a wavelength ranging from about 350 nm to about 850 nm.
35. The upconverting nanoparticle of any one of claims 31-33, wherein the emission spectrum comprises about 1-10 peaks, and wherein each peak has a wavelength ranging from about 860 nm to about 1500 nm.
36. The upconverting nanoparticle of any one of claims 1-35, wherein the at least one upconverting nanoparticle continues to emit a spectrum of radiation at a substantially constant intensity after about 15 hours of exposure to radiation at a wavelength of 976 nm and a power density of about 5-30 kW / cm2.Attomey Docket No.: BRH-05725Broad Ref. No.: BI-11332 37. The upcon verting nanoparticle of any one of claims 1-36, wherein the at least one upconverting nanoparticle emits substantially continuous radiation during exposure to radiation at a wavelength of 976 nm and a power density of about 5-30 kW / cm2.
38. A method of sequencing a peptide, comprising:i. labeling one or more amino acid residues of the peptide with at least one upconverting nanoparticle;ii. irradiating the at least one upconverting nanoparticle;iii. digesting the peptide;iv. irradiating the at least one upconverting nanoparticle;v. measuring the emitted radiation of the at least one upconverting nanoparticle; and vi. determining the sequence of the peptide by correlating a decrease in the measured emitted radiation with the sequence;wherein the spectrum of the measured emitted radiation corresponds to a specific amino acid side chain.
39. The method of claim 38, wherein the at least one upconverting nanoparticle is an upconverting nanoparticle according to any one of claims 1-37.
40. The method of claim 38 or 39, wherein the method further comprises resolving a spatial location of the peptide within a single cell.
41. The method of any one of claims 38-40, wherein the decrease in the measured emitted radiation is a stepwise decrease in the measured emitted radiation.
42. The method of any one of claims 38-41, wherein the one or more amino acid residues of the peptide are selected from lysine, cysteine, arginine, tyrosine, tryptophan, methionine, histidine, aspartate, and glutamate.
43. The method of any one of claims 38-42, wherein labeling one or more amino acid residues of the peptide with at least one upconverting nanoparticle comprises conjugating a first amino acid side chain to an upconverting nanoparticle having a first emission spectrum, and conjugating a second amino acid side chain to an upconverting nanoparticle having aAttomey Docket No.: BRH-05725Broad Ref. No.: BI-11332 second emission spectrum, wherein the first emission spectrum and the second emission spectrum are substantially different.
44. The method of claim 43, further comprising conjugating a third, fourth, fifth, sixth, seventh, eighth, and / or ninth amino acid side chain to an upconverting nanoparticle having a third, fourth, fifth, sixth, seventh, eighth, and / or ninth emission spectrum; wherein each emission spectrum is substantially different.
45. The method of claim 44, wherein the amino acid side chain is selected from a lysine amino acid side chain, a cysteine amino acid side chain, an arginine amino acid side chain, a tyrosine amino acid side chain, a tryptophan amino acid side chain, a methionine amino acid side chain, a histidine amino acid side chain, an aspartate amino acid side chain, and a glutamate amino acid side chain.
46. The method of claim 45, wherein at least one amino acid side chain is a lysine amino acid side chain.
47. The method of claim 45 or 46, wherein at least one amino acid side chain is a cysteine amino acid side chain.
48. The method of any one of claims 45-47, wherein at least one amino acid side chain is an arginine amino acid side chain.
49. The method of any one of claims 45-48, wherein at least one amino acid side chain is a tyrosine amino acid side chain.
50. The method of any one of claims 45-49, wherein at least one amino acid side chain is a tryptophan amino acid side chain.
51. The method of any one of claims 45-50, wherein at least one amino acid side chain is a methionine amino acid side chain.
52. The method of any one of claims 45-51, wherein at least one amino acid side chain is a histidine amino acid side chain.Attomey Docket No.: BRH-05725Broad Ref. No.: BI-11332 53. The method of any one of claims 45-52, wherein at least one amino acid side chain is an aspartate amino acid side chain.
54. The method of any one of claims 45-53, wherein at least one amino acid side chain is a glutamate amino acid side chain.
55. The method of any one of claims 45-54, wherein digesting the peptide comprises: i. contacting the peptide with a degradation reagent; andii. contacting the peptide with an acid.
56. The method of claim 55, wherein the degradation reagent is phenylisothiocyanate (PITC).
57. The method of claim 55 or 56, wherein the acid is trifluoroacetic acid.
58. The method of any one of claims 38-57, wherein the method further comprises repeating steps iii.-vi. for between about 1-50 cycles.
59. The method of claim 58, wherein the method further comprises repeating steps iii.-vi. for between about 1-10 cycles, about 1-20 cycles, about 1-30 cycles, about 1-40 cycles, or about 1-50 cycles.
60. The method of claim 59, wherein the method further comprises repeating steps iii.-vi. for at least about 1 cycle, about 5 cycles, about 10 cycles, about 15 cycles, about 20 cycles, about 25 cycles, about 30 cycles, about 35 cycles, about 40 cycles, or about 45 cycles.
61. The method of claim 59 or 60, wherein the method further comprises repeating steps iii.-vi. for about 30 cycles.
62. The method of any one of claims 38-61, wherein digesting the peptide comprises performing at least one Edman degradation cycle.
63. The method of claim 62, wherein each Edman degradation cycle removes one amino acid residue from the N-terminus of the peptide.Attorney Docket No.: BRH-05725Broad Ref. No.: BI-11332 64. The method of any one of claims 38-63, wherein correlating the measured emitted radiation with the sequence of the peptide comprises integrating an intensity of the measured emitted radiation following steps ii.-v.
65. The method of claim 64, wherein the intensity of the measured emitted radiation is integrated at each cycle.
66. The method of any one of claims 38-65, wherein correlating the measured emitted radiation with the sequence of the peptide comprises measuring at least one change in an intensity of the measured emitted radiation following steps ii.-v.
67. The method of claim 66, wherein measuring the at least one change in the intensity of the measured emitted radiation provides an identity of an amino acid residue that is removed at each cycle.
68. The method of claim 66 or 67, wherein the at least one change in the intensity of the measured emitted radiation is a decrease in the intensity of the measured emitted radiation.
69. The method of claim 68, wherein the decrease is a stepwise decrease.
